Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effects of lenvatinib and pembrolizumab maintenance therapy
in treating patients with pancreatic cancer that has spread to other places in the body
(advanced) and cannot be removed by surgery (unresectable). Lenvatinib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with
monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Giving
lenvatinib and pembrolizumab may be effective as a maintenance therapy in patients with
pancreatic cancer.